

Ref. No: 374151121
From: Commercial
Date: 15/11/21
Subject: Dermatological and rheumatological conditions

REQUEST

I am analysing the usage of new biologic medications for the treatment of dermatological and rheumatological conditions. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients were treated in October 2021 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Bimekizumab (Bimzelx)
- Brodalumab (Kyntheum)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tralokinumab (Adtralza)
- Ustekinumab (Stelara)

Q2. How many patients were treated in October 2021 (or latest available month) by the rheumatology department with the following drugs:

- Baricitinib (Olmiant)
- Filgotinib (Jyseleca)
- Guselkumab (Tremfya)
- Ixekizumab (Taltz)
- Secukinumab (Cosentyx)
- Tofacitinib (Xeljanz)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)

RESPONSE

Question 1

<u>Drug Name</u>	<u>Number of patients treated in October 2021</u>
Abrocitinib (Cibinqo)	0
Baricitinib (Olmiant)	0
Bimekizumab (Bimzelx)	0
Brodalumab (Kyntheum)	0
Dupilumab (Dupixent)	0
Ixekizumab (Taltz)	* <5
Risankizumab (Skyrizi)	* <5
Guselkumab (Tremfya)	* <5
Secukinumab (Cosentyx)	* <5
Tildrakizumab (Ilumetri)	0
Tralokinumab (Adtralza)	0
Ustekinumab (Stelara)	* <5

Question 2

<u>Drug Name</u>	<u>Number of patients treated in October 2021</u>
Baricitinib (Olmiant)	6
Filgotinib (Jyseleca)	0
Guselkumab (Tremfya)	0
Ixekizumab (Taltz)	0
Secukinumab (Cosentyx)	* <5
Tofacitinib (Xeljanz)	0
Upadacitinib (Rinvoq)	0
Ustekinumab (Stelara)	* <5

Please note * <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients cannot be identified.